Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 641-649

  Whiteside, Theresa L ^a,b   Zhao, Yongxiang ^a   Tsukishiro, Takashi ^a   Elder, Elaine M ^a,b   Gooding, William ^a   Baar, Joseph ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOKINE; INTERLEUKIN 4; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TETRAMER; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CANCER PATIENT; CELL ASSAY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; INTERMETHOD COMPARISON; MELANOMA; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RAT; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIGENS, CD; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; LYMPHOCYTE COUNT; MELANOMA; MONITORING, PHYSIOLOGIC; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 0037314635     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Jäger, E., Jäger, D., and Knuth, A. Clinical cancer vaccine trials. Curr. Opin. Immunol., 14: 178-182, 2002.
2. Rosenberg, S. A. Progress in human immunology and immunotherapy. Nature (Lond.), 411: 380-384, 2001.
3. th Edition, pp. 1108-1117. Washington, DC: ASM, 2002.
4. Parmiani, G., Anichini, A., and Fossati, G. Cellular immune responses against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J. Natl. Cancer Inst., 82: 361-370, 1990.
5. Czerkinsky, C. C., Nilsson, L. A., Nygren, H., Ouchterlony, O., and Tankowski, A. A. solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods, 65: 109-121, 1983.
6. Suni, M. A., Picker, L. J., and Maino, V. C. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J. Immunol. Methods, 212: 89-98, 1998.
7. Altman, J. D., Moss, P. A. H., Goulder, P., Jr., Banouch, D. H., McHeyzen-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science (Wash. DC), 274: 94-96, 1996.
8. Herr, W., Wolfel, T., Heike, M., Meyer zum Buschenfelde, K. H., and Knuth, A. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunol. Immunother., 39: 93-99, 1994.
9. Meidenbauer, N., Gooding, W., Spliter, L., Harris, D., and Whiteside, T. L. Recovery of ζ chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. Br. J. Cancer, 86: 168-178, 2002.
10. Jameson, J., Cruz, J., and Ennis, F. A. Human cytotxic T-lymphocyte repertoire to influenza A virus. J. Virol., 72: 8682-8689, 1998.
11. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat. Med., 4: 953-956, 1998.
12. Kuzushima, K., Hoshino, Y., Fujii, K., Yokoyama, N., Fujita, M., Kiyono, T., Kimura, H., Morishima, T., Morishima, Y., and Tsurumi, T. Rapid determination of Epstein-Barr virus-specific CD8(+) T-cell frequencies by flow cytometry. Blood, 94: 3094-3100, 1999.
13. Pitcher, C. J., Quittner, C., Peterson, D. M., Connors, M., Koup, R. A., Maino, V. C., and Picker, L. J. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med., 5: 518-525, 1999.
14. Karabujas, V., Lodding, J., Maino, V. C., and McKenzie, I. F. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin. Cancer Res., 6: 829-837, 2000.
15. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M., and Davis, M. M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5: 677-685, 1999.
16. + T cells after vaccination with antigenic peptide. Clin. Cancer Res., 7: 7965-8035, 2001.
17. Hoffmann, T. K., Donnenberg, V., Friebe-Hoffmann, U., Meyer, M., Rinaldo, C. R., DeLeo, A. B., Whiteside, T. L., and Donnenberg, A. D. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex. Cytometry, 41: 321-328, 2000.
18. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis a. J. Exp. Med., 179: 1109-1118, 1994.
19. + hemotopoietic precursor cells. Blood, 87: 535-544, 1996.
20. Asai, T., Storkus, W. J., and Whiteside, T. L. Evaluation of the modified ELISPOT assay for interferon-γ production in monitoring of cancer patients receiving anti-tumor vaccines. Clin. Diagnostic Lab. Immunol., 7: 145-154, 2000.
21. Renkvist, N., Castelli, C., Robbins, P. F., and Parmiani, G. A. listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunther., 50: 3-15, 2001.
22. Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, R. M., and Anichini, A. Cancer immunotherapy with peptide-based vaccines: what have we achieved: where are we going? J. Natl. Cancer Inst., 94: 805-818, 2002.
23. Jäger, E., Maeurer, M., Hölm, H., Karbach, J., Jager, D., Zidianakis, Z., Bakhshandeh-Bath, A., Orth, J., Neukirch, C., Necker, A., Reichert, T. E., and Knuth, A. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int. J. Cancer, 86: 538-547, 2000.
24. Banchereau, J., Palucka, A. K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., Pineiro, L., Steinman. R., and Fay, J. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine, Cancer Res., 61: 6451-6458, 2001.
25. Jäger, E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, J., Jäger, D., Oesch, F., and Knuth, A. Immunoselection. in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer, 71: 142-147, 1997.
26. Clay, T. M., Hobeika, A. C., Mosca, P. J., Lyerly, K. H., and Morse, M. A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res., 7: 1127-1135, 2001.
27. Whiteside, T. L. Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense. Immunol. Investig., 29: 149-162, 2000.
28. Keilholz, U., Weber, J., Finke, J. H., Gabrilovich, D. I., Kast, W. M., Disis, M. L., Kirkwood, J. M., Scheibenbogen, C., Schlom, J., Maino, V. C., et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother., 25: 97-138, 2002.
29. Maino, V. C., and Picker, L. J. Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 34: 207-215, 1998.
30. Walker, E., Smith, J. W., III, Hu, H-M., Romero, P., Fox, B. A., and Urba, W. J. Immunomonitoring of gp100 peptide (209-2M) immunized melanoma patients: comparative analysis using ELISPOT detection, cytokine flow cytometry and a tetramer binding assay. Proc. Am. Assoc. Cancer Res., 43: 82, 2002.
31. Schultes, B. C., Gordon, A., Ehlen, T., Nicodemus, C. F., Fingert, H., Edwards, R., and Whiteside, T. L. Induction of tumor-and CA125-specific T cell responses in patients with epithelial ovarian cancer (EOC) treated with OvaRex® Mab-B43.13 Proc. Am. Assoc. Cancer Res., 43: 144, 2002.
32. Bennouna, J., Hildesheim, A., Chikamatsu, K., Gooding, W., Storkus, W. J., and Whiteside, T. L. Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. J. Immunol. Methods, 261: 145-156, 2002.
33. Maecker, H. T., Auffermann-Gretzinger, S., Nomura, L. E., Liso, A., Czerwinski, D. K., and Levy, R. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. Clin. Cancer Res., 7: 902s-908s, 2001.
34. + peripheral blood T lymphocytes of patients with melanoma. Clin. Cancer Res., 7: 947-957, 2001.
35. Hoffmann, T. K., Dworacki, G., Meidenbauer, N., Gooding, W., Johnson, J. T., and Whiteside, T. L. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin. Cancer Res., 8: 2553-2562, 2002.
36. Nomura, L. E., Walker, J. M., and Maecker, H. T. Optimization of whole blood antifen-specific cytokine assays for CD4(+) T cells. Cytometry, 40: 60-68, 2000.
37. Coulie, P. G., Karanikas, V., Colau, D., Lurquin, C., Landry, C., Marchand, M., Dorval, T., Brichard, V., and Boon, T. A. monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA, 98: 10290-10295, 2001.
38. + cytotoxic T lymphocytes. J. Exp. Med., 181: 363-368, 1995.
39. Reichert, T. E., Strauss, L., Wagner, E. M., Gooding, W., and Whiteside, T. L. Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin. Cancer Res., 8: 3137-3145, 2002.